

Case Report

A Case of Post Viral Acute Longitudinal Extensive Transverse Myelitis (LETM): MOGAD- A New Horizon

Richmond Ronald Gomes¹

DOI: <https://doi.org/10.3329/bccj.v12i1.72402>

Abstract:

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a recently identified autoimmune disorder that presents in both adults and children. It is a group of central nervous system demyelinating diseases caused by auto antibodies against myelin oligosaccharide protein, a myelin sheath component protein, and present with a variety of symptoms, including optic neuritis, longitudinal extensive transverse myelitis (LETM), acute disseminated encephalomyelitis (ADEM), brainstem encephalitis, and corticobasal encephalitis. Although there are clinical phenotypic overlaps between MOGAD, multiple sclerosis, and aquaporin-4 antibody-associated neuromyelitis optica spectrum disorder (NMOSD) cumulative biological, clinical, and pathological evidence discriminates between these conditions. Here, we present a case of a young male with acute onset of spastic paraplegia with sphincters involvement and patchy loss of pinprick sensation with positive Anti-MOG Antibody shortly after viral febrile illness.

Key Words: MOGAD, ADEM, LETM, NMOSD, demyelinating disease, spastic paraplegia

Introduction:

Myelin-oligodendrocyte glycoprotein (MOG) constitutes a quantitatively minor component (0.05%) of CNS myelin¹ and is expressed on the outer lamella of the myelin sheath.^{1,2} which makes it particularly susceptible to immune-mediated demyelination. In humans MOG is thought to be involved in completion and maintenance of the myelin sheath and in cell-cell communication. Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) is an inflammatory disease of the Central Nervous System (CNS) characterized by attacks of immune-mediated demyelination. Its clinical course can be monophasic or relapsing, with clinical presentation resembling Acute Disseminated Encephalomyelitis (ADEM), Optic Neuritis (ON), transverse myelitis, and brainstem demyelinating syndrome. The spinal cord presentation of MOGAD may be in the form of: a) longitudinally extensive transverse myelitis (involving three or more vertebral segments) or b) short lesions involving less than two vertebral segments^{3,4}. The involvement of conus medullaris is observed more in MOGAD spectrum than any other reported demyelinating disorders^{4,6}.

Although there are clinical phenotypic overlaps between MOGAD, multiple sclerosis, and neuromyelitis optica spectrum disorder (NMOSD) associated with anti-aquaporin-4 (AQP4) antibodies (AQP4-NMOSD),

cumulative biological, clinical, and neuropathological evidence clearly discriminates between these conditions. While patients with MS, MOGAD and NMOSD may present with similar clinical manifestations, such as optic neuritis and myelitis, those with MOGAD lack a clear sex predilection, and more commonly experience a monophasic course^{7,8}. MOGAD also has the greatest predilection in children, representing 20–30% of inflammatory CNS syndromes in this population as compared to approximately 5% in adults. The current estimated range of incidence in the pediatric population is 3.1 per 1 million, as compared to 1.6 and 2.39 per 1 million among adults⁸. Diagnostic criteria of MOGAD required presence of core clinical demyelinating event which includes optic neuritis, transverse myelitis, Acute Disseminated Encephalomyelitis, cerebral monofocal or polyfocal deficits, brainstem or cerebellar deficits, cerebral cortical encephalitis, often with seizures⁹, positive MOG antibody and exclusion of other diagnosis.

Case report:

A 22 years old man presented to the emergency department with high grade, intermittent fever (highest being recorded as 104° F) for 3 days along with runny nose, dry cough, headache and generalized bodyache. He had no other focal systemic complaints. Both general and systemic examination revealed no significant abnormalities apart from raised temperature. Initial investigations revealed normal complete blood count with normal differentials. CRP, liver function tests, renal function tests, chest x-ray were normal. Dengue NS1 antigen and COVID antigen were negative. He became afebrile in the next 2 days. He was diagnosed as viral fever and planned to be discharged. The night before discharge, he developed severe bilateral, symmetrical thigh and calf muscle pain along with weakness. There was also nocturnal urinary incontinence. He had no history of numbness, paresthesia and backache. There

1. Professor, Medicine, Ad-din Women's Medical College Hospital, Dhaka.

*Corresponding Author:

Prof. Richmond Ronald Gomes
Professor, Medicine
Ad-din Women's Medical College Hospital, Dhaka Bangladesh
E-mail: rrichi.dmc.k56@gmail.com
Orchid ID: 0000000225117972

was no history of visual impairment, dysarthria, dysphagia, no history of nasal regurgitation, no breathing difficulty. He had no medical history, in particular, no history of TB contact. Family history was not significant. He was unmarried, student and belonged to a middle income family. He was a non-smoker, not taking any medications regularly. On examination, his upper limbs had normal tone with MRC grade 5 power, and his deep tendon reflexes were intact. In lower limbs, he had 3/5 power in proximal and distal muscles bilaterally according to MRC grading, with increased tone and grade 3 deep tendon reflexes with sustained ankle clonus. His plantar reflexes were bilaterally extensor. There was no muscle tenderness. Cerebellar functions were intact in both upper limbs. In lower limbs, cerebellar functions could not be assessed due to reduced muscle power. His gait could not be assessed. On sensory system examination, there was patchy impairment of sensations in thighs and some parts of calves but no definite sensory level. Joint position & vibration sensation was intact. No gross spinal deformity and no spinal tenderness was present.

On eye examination, his pupils were bilaterally equal and reactive to light, with intact extraocular movements. His visual acuity was normal and there is no relative afferent pupillary defect, colour vision impairment or disc pallor. The rest of the cranial nerves examination was unremarkable. There were no signs for meningeal irritation. His cardiovascular, respiratory and gastrointestinal examination was unremarkable. On the very next day his lower limb weakness progressed to such degree that he became bed bound with muscle power 0/5.

Repeat laboratory analysis demonstrates normal complete blood count, renal and liver function tests, serum electrolytes, coagulation profile, and urine routine examination. His hepatitis B and C screening was negative. Cerebrospinal fluid analysis was done which revealed mildly increased protein with 77 mg/dl, normal glucose, mild lymphocytic pleocytosis (total cell 80/cmm, Lymphocyte 98%).

MRI was performed within 48 h of the onset of paraparesis, which revealed a long-segment, intramedullary, expansile, heterogeneously enhancing spinal cord lesion extending from T4 vertebral level till conus medullaris with no post-contrast enhancement, likely due to inflammatory demyelinating aetiology. Few foci of blooming were also noted in the spinal cordon gradient sequences (Fig 1). MRI of Brain with contrast done which was reported as an essentially unremarkable study with no evidence of demyelinating plaques or any other significant abnormality. His HIV serology and VDRL were negative. NMO (aquaporin-4 IgG) was not available. The anti-MOG antibody test is strongly positive (> 1:100) in this patient. A diagnosis of MOGAD-associated longitudinally extensive transverse myelitis was made.



Figure 1: T2W sagittal image showing a long-segment T2 hyperintense signal extending from T4 upto conus medullaris, with few hypointense area in between.



Figure 2: Follow-up MRI images after 14 days. T2 sagittal image showing significant reduction in the T2 hyperintensities within the spinal cord.

The patient was started on IV methylprednisolone 1 g/day for 5 days oral prednisolone 1mg/kg/day for next 10 days. Physiotherapy was ensured. Two weeks following treatment, the patient gradually improved and regained his ability to walk with muscle power 4/5 in both lower limbs. Follow up MRI of spine at two weeks revealed significant decrease in the spinal cord lesion (Fig. 2) suggesting good response to the treatment and establishing the diagnosis of MOGAD-positive longitudinally extensive transverse myelitis.

Discussion:

Myelin oligodendrocyte glycoprotein (MOG) is a protein on the surface of oligodendrocytes, is highly immunogenic and its exact function is unknown; it may act as a cell adhesion molecule, and its location on the outermost part of myelin

sheath makes it more susceptible to immune-mediated CNS demyelination. It is a minor component of myelin sheath comprising 0.5%¹⁰. It was previously considered a potential antibody target for Multiple sclerosis patients, but since 2007 MOG-associated Immunoglobulin G (IgG) is considered a separate demyelinating disease. It is a rare autoimmune disorder¹¹. MOG-IgG-associated disorders present mostly as Acute Disseminated Encephalomyelitis (ADEM) in children, optic neuritis, and severe myelitis in adults. Currently, few studies showed that it can present as brainstem and autoimmune encephalitis¹². MOG-associated antibody disease showed a female predominance as compared to males¹³. MOGAD accounts for approximately 1.2–6.5% of all demyelinating syndromes in adults.^{14,15} Proposed MOGAD diagnostic criteria is summarized in Table I.

Table I : Proposed MOGAD diagnostic criteria by an international panel of experts. This table is adapted from Banwell et al., 2023⁹

MOGAD diagnosis necessitates the fulfillment of 1, 2 and 3		
1. Clinical demyelinating event	Optic neuritis Myelitis ADEM Cerebral, brainstem or cerebellar deicits Cerebral cortical encephalitis	
2. Positive MOG-IgG test	Clear positive [titer ≥ 1:100] Low positive [titer ≥ 1:10 and < 1:100] Positive without reported titer Serum negative but CSF positive	No additional supporting features required A & B must be true A) AQP4-IgG seronegative B) One or more supportin clinical or MRI features ψ
3. Exclusion of better diagnoses, including MS		
ψ Supporting clinical and MRI features		
Optic neuritis		Simultaneous bilateral optic nerve involvement Longitudinal optic nerve involvement [> 50% of the optic nerve length] Optic disk edema/swelling Perineural optic sheath enhancement
Myelitis		Longitudinally extensive myelitis (LETM) Conus lesion H-sign or central cord lesion
Brain, brain stem, or cerebral Syndrome		Deep gray matter involvement Multiple ill-deined T2 hyper-intense lesions in the supra-tentorial and Infra tentorial white matter Cortical lesion with or without lesional and overlying meningeal enhancement Ill-deined T2-hyperintensity involving medulla, pons, or middle cerebellar peduncle

MOGAD MOG antibody-associated disease, ADEM acute disseminated encephalomyelitis, MRI magnetic resonance imaging, AQP4 aquaporin 4, CSF cerebral spinal fluid, MS multiple sclerosis

Transverse myelitis is an initial presentation mainly in adults who are seropositive for MOGAD. It is a severe, disabling condition, and with the help of antibody assessment for NMOSD and MOG, we are able to identify the causes of transverse myelitis. MOG-IgG-associated myelitis presents as acute spastic myelitis. MOG-AD transverse myelitis is mostly longitudinally extensive (LETM). As in our case, MRI dorsolumbar spine showed a longitudinally extensive lesion extending from mid-thoracic region to conus. It showed no post-contrast enhancement as compared to AQP4-IgG seropositive myelitis. Deep grey matter lesions are more common in MOG-IgG myelitis¹⁵. It can also be associated with optic neuritis and brainstem encephalitis. We can differentiate MOG-AD from NMOSD and MS, although there are few clinical and radiological similarities between MOG-AD and NMOSD but can easily differentiate from MS. Silent lesions which are commonly found in MS are absent in MOGAD¹⁶. MOGAD has the greatest predilection for conus medullaris resulting in sphincter involvement and bladder dysfunction¹⁷.

Biomarkers:

Assays for anti-MOG antibody detection: Over the last 10 years, great efforts have been made to improve anti-MOG antibody detection techniques. More consistent results were obtained when the substrate for the tests were recombinant antigens expressed on live cells. Their titres are higher during the acute attack in young children than in adolescents or adults¹⁸ but more likely to become negative after the attack.²⁰ Timing of testing is important as antibody titres fluctuate and can decrease over months from presentation, and some patients can subsequently be tested negative.¹⁹ Anti-MOG antibodies are now rarely found in patients with typical multiple sclerosis using cell-based assays. It is exceptionally rare for any patient to have serum antibodies to both MOG and AQP4.^{14,20} Finally, the usefulness of anti-MOG antibody detection in the CSF is not yet fully evaluated. When paired samples are analysed, there is a good concordance between serostatus and CSF status (ie, most CSF-positive patients are seropositive), but not all seropositive patients are CSF-positive, and only a small proportion are seronegative and CSF-positive.²¹

Imaging biomarkers:

Brain and spinal cord MRI: Brain MRI in MOGAD can be abnormal in more than 50% of patients, regardless of the clinical presentation.¹⁴ In general, brain lesions are more wide spread in children than in adults, reflecting a higher disease burden. In addition to the deep white and grey matter lesions found in acute disseminated encephalomyelitis-like presentations, brainstem lesions are found in up to 40% of patients with MOGAD, frequently involving the pons and middle cerebellar peduncles.²²⁻²⁵ Although initially thought to be associated predominantly with white matter disease, both adults and children with MOGAD can experience cortical encephalitis and seizures. Brain MRI in these patients can be normal or have reversible cortical changes occasionally with leptomeningeal enhancement.

Spinal cord MRI findings in MOGAD such as the presence of longitudinally extensive T2 lesions, spanning at least three vertebral segments on sagittal sequences, or the hyperintensity of grey matter on axial sequences (longitudinally extensive transverse myelitis), can resemble those commonly seen in AQP4-NMOSD.⁵ MRI features suggesting a diagnosis of MOGAD rather than AQP4-NMOSD or multiple sclerosis are involvement of the conus medullaris, abnormality confined to grey matter (sagittal line and axial H sign) and nerve roots, and scarcity of or minimal gadolinium enhancement.⁵

Treatment:

Attack treatment: There are currently no randomised control trials or evidence-based guidelines for the acute treatment of MOGAD. First line immunotherapy therefore consists of intravenous methylprednisolone (30 mg/kg per day or 1 g per day, for 3–5 days). Treatment escalation is warranted for patients who do not improve after intravenous methylprednisolone or individuals with a severe attack such as complete loss of vision, paralysis, or severe encephalopathy requiring admission to intensive care. Escalation therapies include plasma exchange (five exchanges on alternative days), immunoadsorption, intravenous immunoglobulins (total of 2 g/kg over 2 or 5 days), or plasma exchange followed by intravenous immunoglobulins.²⁶

Chronic treatment for relapse prevention: The accumulation of disability in patients with antibody mediated diseases, such as MOGAD, is thought to be primarily relapse related. Because of the risk of disability due to incomplete relapse recovery, identifying patients at risk for relapse, and treating those with relapses, is the focus of current management. Currently there are no predictors of relapse risk and long-term outcome. No clinical trials have been done for patients with MOGAD and the current literature reports real-world clinical data, which are not optimal for evaluation of treatment efficacy. Data from the six largest retrospective studies on treatment of relapsing MOGAD^{3,27,28} revealed that, at a median of 9–16 months after the start of treatment, the number of relapse free patients was 20 (69%) of 29 patients on intravenous immunoglobulin monotherapy, 30 (47%) of 63 on mycophenolate mofetil, 21 (39%) of 55 on azathioprine, and 47 (50%) of 94 on rituximab. Of note, although anti-CD20 therapy seems to show some effect, it appears to be less efficacious than in AQP4-NMOSD²⁹. There are only anecdotal reports for use of alemtuzumab, dimethyl fumarate, and fingolimod, precluding judgment of treatment efficacy.

Prognosis:

The duration of immunosuppressive treatment for MOGAD remains uncertain, as the field currently lacks robust biomarkers to inform therapy. Specifically, it is challenging to identify patients who will remain monophasic after their first attack. Several indicators of disease activity have been proposed, including attack severity and frequency, MOG-IgG sero-status and titers, patient age, relapse-free interval, spinal cord involvement, and resultant neurological disability^{30,31}. The identification of prognostic factors indicating the

likelihood of relapse and disability in a patient would catalyze a personalized treatment approach for MOGAD patients.

Adult MOGAD patients tend to have more recurrent episodes and poorer functional recovery compared to pediatric patients. Nevertheless, recurrent disease has been associated with elevated initial MOG-IgG titers, while transiently low titers have been shown to be associated with a monophasic course^{32,33}. Long-term outcomes and disability are quite challenging to predict as studies with long follow-up are sparse for patients with MOGAD. While it is believed that, on average, even frequently relapsing MOGAD results in less disability than NMOSD, inter-patient variability has been documented³⁴. Sufficiently powered prospective studies with extended follow-up would enable a more comprehensive understanding of the natural history of MOGAD, identify predictors of its course and establish guidelines for its treatment.

Conclusion:

Post infectious longitudinally extensive transverse myelitis (LETM) as a standalone finding without any involvement of optic nerves and brain may show MOGAD seropositivity and should be considered as one of the differential diagnosis in cases of acute myelopathy.

Conflict of interest: None declared

References:

1. Johns TG, Bernard CC. The structure and function of myelin oligodendrocyte glycoprotein. *J Neurochem* 1999; 72: 1–9.
2. Reindl M, Di Pauli F, Rostásy K, Berger T. The spectrum of MOG autoantibody-associated demyelinating diseases. *Nat Rev Neurol* 2013; 9: 455–61.
3. Jarius S, Ruprecht K, Kleiter I, Cooperation with the Neuromyelitis Optica Study Group (NEMOS) et al (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. *J Neuroinflamm* 13(1):280. <https://doi.org/10.1186/s12974-016-0718-0>.
4. Kitley J, Waters P, Woodhall M, Leite MI et al (2014) Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. *JAMA Neurol* 71(3):276–283.
5. Dubey D, Pittock SJ, Krecke KN et al (2019) Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. *JAMA Neurol* 76(3):301–309.
6. Kitley J, Leite MI, Küker W et al (2013) Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies. *JAMA Neurol* 70(11):1375–1381.
7. Costello F (2022) Neuromyelitis optica spectrum disorders. *Contin Lifelong Learn Neurol* 28:1131–1170. <https://doi.org/10.1212/CON.000000000001168>.
8. Longbrake E (2022) Myelin oligodendrocyte glycoprotein-associated disorders. *Contin Lifelong Learn Neurol* 28:1171–1193. <https://doi.org/10.1212/CON.000000000001127>.

9. Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, et al. (2023) Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International Mogad Panel proposed criteria. *Lancet Neurol* 22: 268–282.
10. Dos Passos GR, Oliveira LM, da Costa BK, Apostolos-Pereira SL, Callegaro D, et al. (2018) Mog-IgG-associated optic neuritis, encephalitis, and myelitis: Lessons learned from Neuromyelitis Optica Spectrum disorder. *Front Neurol* 9: 217.
11. Salama S, Khan M, Pardo S, Izbudak I, Levy M (2019) Mog antibody-associated encephalomyelitis/encephalitis. *Mult Scler* 25: 1427–1433.
12. Hegen H, Reindl M (2020) Recent developments in Mog-IgG Associated Neurological Disorders. *Ther Adv Neurol Disord* 13.
13. Paige Sutton, Lutz MW, Hartsell FL, Kimbrough D, Tagg NT, et al. (2022) Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: Presentation and outcomes of adults at a single center. *J Neuroimmunol* 373:577987.
14. Cobo-Calvo Á, d'Indy H, Ruiz A, et al. Frequency of myelin oligodendrocyte glycoprotein antibody in multiple sclerosis: a multicenter cross-sectional study. *Neurol Neuroimmunol Neuroinflamm* 2019; 7: e649.
15. Kunchok A, Chen JJ, McKeon A, Mills JR, Flanagan EP, Pittock SJ. coexistence of myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies in adult and pediatric patients. *JAMA Neurol* 2020; 77: 257–59.
16. Juryńczyk M, Jacob A, Fujihara K, Palace J (2019) Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: Practical considerations. *Pract Neurol* 19: 187–195.
17. Sechi E, Cacciaguerra L, Chen JJ, Mariotto S, Fadda G, et al. (2022) Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): A review of clinical and MRI features, diagnosis, and Management. *Front Neurol* 13:885218.
18. Pröbstel AK, Rudolf G, Dornmair K, et al. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. *J Neuroinflammation* 2015; 12: 46..
19. Waters P, Fadda G, Woodhall M, et al. Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes. *JAMA Neurol* 2020; 77: 82–93.
20. Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. *Nat Rev Neurol* 2019; 15: 89–102.
21. Mariotto S, Gajofatto A, Batzu L, et al. Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases. *Neurology* 2019; 93: e1867–72.
22. Hacohen Y, Mankad K, Chong WK, et al. Diagnostic algorithm for relapsing acquired demyelinating syndromes in children. *Neurology* 2017; 89: 269–78.
23. Juryńczyk M, Gerales R, Probert F, et al. Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis. *Brain* 2017; 140: 617–27.
24. Baumann M, Grams A, Djurdjevic T, et al. MRI of the first event in pediatric acquired demyelinating syndromes with antibodies to myelin oligodendrocyte glycoprotein. *J Neurol* 2018; 265: 845–55.
25. Juryńczyk M, Tackley G, Kong Y, et al. Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease. *J Neurol Neurosurg Psychiatry* 2017; 88: 132–36.
26. Hacohen Y, Banwell B. Treatment approaches for MOG-Ab-associated demyelination in children. *Curr Treat Options Neurol* 2019;21:2.

27. Hacohen Y, Wong YY, Lechner C, et al. Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. *JAMA Neurol* 2018; 75: 478–87.
28. Ramanathan S, Mohammad S, Tantsis E, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. *J Neurol Neurosurg Psychiatry* 2018; 89: 127–37.
29. Durozard P, Rico A, Boutiere C, et al. Comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases. *Ann Neurol* 2020; 87: 256–66.
30. Li S, Ren H, Xu Y, et al (2020) Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders. *Neuroinflammation* 7:e705. <https://doi.org/10.1212/NXI.0000000000000705>.
31. Havla J, Pakeerathan T, Schwake C et al (2021) Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well? *J Neuroinflammation* 18:121. <https://doi.org/10.1186/s12974-021-02160-9>.
32. Cobo-Calvo A, Ruiz A, Rollot F et al (2021) Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. *Ann Neurol* 89:30–41. <https://doi.org/10.1002/ana.25909>.
33. Juryńczyk M, Messina S, Woodhall MR et al (2017) Clinical presentation and prognosis in MOG-antibody disease: a UK study. *Brain* 140:3128–3138. <https://doi.org/10.1093/brain/awx276>.
34. Chen JJ, Flanagan EP, Jitprapaikulsan J et al (2018) Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome. *Am J Ophthalmol* 195:8–15. <https://doi.org/10.1016/j.ajo.2018.07.020>.